GSK (LON:GSK) Insider Purchases £73,981.46 in Stock

GSK plc (LON:GSK) insider Wendy Becker bought 3,334 shares of GSK stock in a transaction dated Friday, February 20th. The shares were acquired at an average cost of GBX 2,219 per share, for a total transaction of £73,981.46.

Wendy Becker also recently made the following trade(s):

• On Friday, December 19th, Wendy Becker bought 441 shares of GSK stock. The shares were acquired at an average price of GBX 1,809 per share, with a total value of £7,977.69.

GSK Price Performance

GSK traded down GBX 2.84 on Friday, hitting GBX 2,223.16. 32,758,625 shares of the company’s stock traded hands, compared to its average volume of 9,753,256. The company’s 50 day simple moving average is GBX 1,915.02 and its 200-day simple moving average is GBX 1,716.42. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64. GSK plc has a one year low of GBX 1,242.50 and a one year high of GBX 2,282. The firm has a market cap of £89.70 billion, a price-to-earnings ratio of 16.72, a P/E/G ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK) last issued its earnings results on Wednesday, February 4th. The company reported GBX 172 earnings per share for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. As a group, research analysts anticipate that GSK plc will post 175.980975 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a report on Wednesday, January 7th. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 2,100 price target on shares of GSK in a report on Wednesday, January 7th. Citigroup upped their target price on GSK from GBX 1,900 to GBX 2,250 and gave the company a “buy” rating in a research report on Monday, February 9th. Berenberg Bank lifted their price target on GSK from GBX 1,600 to GBX 1,660 and gave the stock a “hold” rating in a research report on Monday, November 24th. Finally, Deutsche Bank Aktiengesellschaft raised their price objective on GSK from GBX 1,600 to GBX 1,675 and gave the stock a “hold” rating in a research note on Thursday, January 15th. Three equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of GBX 1,917.86.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.